about
The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatinEffects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARsAnticachectic effects of formoterol: a drug for potential treatment of muscle wasting.Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?Differential expression of neurogenes among breast cancer subtypes identifies high risk patients.The neuronal influence on tumor progression.Effects of formoterol on protein metabolism in myotubes during hyperthermia.Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model.Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia.Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load.A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation–contraction coupling together with additional muscle alterations.Patterns of gene expression in muscle and fat in tumor-bearing rats: effects of CRF2R agonist on cachexia.Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of 2-Adrenergic AgonistsResveratrol does not ameliorate muscle wasting in different types of cancer cachexia models
P50
Q28474925-45D2A95F-8A22-4550-8FC4-6B3A276C258DQ28567700-023AA802-4A4B-4639-9F1F-56790F3177E5Q34550960-BE223A6C-F092-432E-9F29-A9A8F41134CFQ34716943-C52C7080-65D4-4F2B-ADE6-6C30419866B5Q36905647-152C23C6-8422-4047-83AC-C6EE99359729Q37880353-FAE9734C-308E-4A1E-9B1D-50CA5114C4C9Q39604824-7A99DF64-7D05-4502-B4B8-57B7432CD089Q39639061-4CE2BED8-4BBA-4183-9671-4DD7CDBBDD62Q40319010-2C92B179-37E8-4C45-8882-30A04ED2E04AQ42444701-09E3ACDF-F719-491E-9750-00802D135516Q42633379-59E50F9E-8B96-4DB2-999C-A71FBD8577BDQ45855217-94835880-9C14-4A26-8CFB-4ED140CA9A83Q46928126-D71C4A18-27E9-4730-B1CA-7D8500037C55Q51015339-CC01FAA3-1A03-4410-946A-59C151B9781FQ54400557-546D46BE-E535-4A08-8812-2F73ADDFC65CQ60403659-4BC210F8-2089-4F71-A03B-9CFBC07BFD46Q60403665-E04D5E5B-E53A-45C0-A920-2D6BBDDE46E2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisabet Ametller
@ast
Elisabet Ametller
@en
Elisabet Ametller
@es
Elisabet Ametller
@nl
type
label
Elisabet Ametller
@ast
Elisabet Ametller
@en
Elisabet Ametller
@es
Elisabet Ametller
@nl
prefLabel
Elisabet Ametller
@ast
Elisabet Ametller
@en
Elisabet Ametller
@es
Elisabet Ametller
@nl
P106
P1153
6504425755
P31
P496
0000-0001-9947-7033